Rahul Gosain, Director of Regional Infusion Services at shared a post on LinkedIn:
“Nivo was approved in Melanoma in 2014. A decade later, we’ve 20+ indications. We discuss the recent Sub-cutaneous approval of Nivo with Saby George, from Roswell Park Comprehensive Cancer Center.”